Phase II Clinical Study of Probiotic LR607 in Patients With Non-Small Cell Lung Cancer
Recruiting
Phase 2
Interventional Study
NSCLC Diagnosed by Histology or Cytology
A Multidisciplinary Team Assessment Determined That the Patient Was a Suitable Candidate for Radical Surgical Resection
Overall Lung Function is Adequate for the Planned Lung Resection
AJCC is Classified as IB-IIIC
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 18 – 80
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 46 (estimated)
- Sponsor
- Zhujiang Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this clinical trial is to understand whether Lactobacillus rhamnosus LR607 can enhance neoadjuvant chemoimmunotherapy for adult patients with non-small cell lung cancer. It will also evaluate the safety of LR607. The main questions it aims to answer include:
Can LR607 improve the major pathological response of neoadjuvant chemoimmunotherapy? What is the relationship between LR607 comb…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Histologically confirmed newly diagnosed patients
2. ECOG performance status 0-1
3. Age ≥18 years
4. Measurable lesions (RECIST v1.1)
5. Organ function meeting the requirements for chemotherapy and immunotherapy.
Exclusion Criteria:
1. Including active autoimmune diseases
2…
Contacts